| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Ginsenoside Rc targets multiple cellular processes and pathways. It modulates cell growth, differentiation, and apoptosis. It inhibits diabetic cardiomyopathy by reducing lipotoxicity through the adiponectin and autophagy pathways. It also maintains sleep homeostasis by alleviating oxidative stress. It interacts with specific cellular receptors and signaling molecules.
|
|---|---|
| ln Vitro |
One of the main ginsenosides in Panax ginseng, ginsenoside Rc, is known to improve ion channel currents mediated by gamma-aminobutyric acid (GABA) receptor A (GABAA). In oocytes receiving GABA, ginsenoside Rc increases GABAA-mediated expression [1]. Ginsenoside Rc also significantly suppresses the expression of cytokines derived from macrophages, including IL-1β and TNF-α. Additionally, in macrophage-activated RAW264.7 macrophages, human synovial cells, and HEK293 cells, ginsenoside Rc significantly inhibits the activation of TANK-binding switch 1/IκB pathway epsilon/interferon regulatory factor 3 and p38/ATF-2 signaling. ..Ginsenoside Rc controls the expression of p38/ATF-2 and ε/interferon regulatory factor 3 in the TANK binding switch 1/IκB pathway. While ginsenoside Rc treatment does not, it inhibits the nuclear translocation of phosphorylated FRA-1 and phosphorylated ATF-2. By blocking AP-1 activation, ginsenoside Rc inhibits the translocation of p65 at the highest time points (30 and 60 minutes), which controls the expression of pro-inflammatory cytokine TNF-α released by macrophages [2].
In vitro, Ginsenoside Rc has been shown to have antioxidative and anti-aging properties. It inhibits the growth of various cancer cell lines. It modulates gene expression and protein synthesis, affecting various cellular processes. Its effects on adiponectin and autophagy pathways have been demonstrated in cellular models. |
| ln Vivo |
In vivo, Ginsenoside Rc has been shown to inhibit diabetic cardiomyopathy by reducing lipotoxicity. It maintains sleep homeostasis by alleviating oxidative stress. It also has anti-tumor properties in animal models. These effects highlight its potential as a therapeutic agent for metabolic and neurological disorders.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Ginsenoside Rc are not specifically detailed in the search results. However, its effects on molecular pathways suggest it may interact with various enzymes and receptors. Its modulation of adiponectin and autophagy pathways implies potential interactions with related proteins.
|
| Cell Assay |
In vitro cell-based assays for Ginsenoside Rc involve treating various cell types to assess its effects on cell viability, gene expression, and signaling pathways. Its effects on oxidative stress and autophagy are studied using specific cellular models. Its anti-cancer activity is evaluated using cancer cell lines.
|
| Animal Protocol |
In vivo animal experiments for Ginsenoside Rc have been conducted in models of diabetic cardiomyopathy and sleep disorders. The compound is typically administered orally or via injection, and its effects on disease progression and related biomarkers are assessed.
|
| ADME/Pharmacokinetics |
Ginsenoside Rc is extracted from ginseng. Specific pharmacokinetic data, such as absorption, distribution, metabolism, and excretion, are not detailed in the available sources. As a saponin, its oral bioavailability may be limited, but it is still considered a bioactive compound.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Ginsenoside Rc is not provided in the search results. As a component of Panax ginseng, it is generally considered safe, but detailed toxicological studies would be required for clinical development. It has antioxidative and anti-aging properties, suggesting a potential protective role.
|
| References |
|
| Additional Infomation |
Ginsenoside Rc is a ginsenoside found in ginseng, with a dammarane-type structure, where hydroxyl groups are substituted at the 3β, 12β, and 20 pro-S positions. Specifically, the hydroxyl groups at positions 3 and 20 are converted to the corresponding β-D-glucopyranosyl-(1→2)-β-D-glucopyranoside and α-L-arabinofuranosyl-(1→6)-β-D-glucopyranoside, respectively, and a double bond is introduced at positions 24-25. It is a plant metabolite and a hypoglycemic agent. It is a 12β-hydroxysteroid, β-D-glucoside, disaccharide derivative, ginsenoside, and tetracyclic triterpenoid compound. It is derived from the hydride of dammarane. Ginsenoside Rc has been reported to exist in ginseng, Japanese ginseng, and other organisms with relevant data. See also: American ginseng (partial); Asian ginseng (partial); Panax notoginseng root (partial).
Ginsenoside Rc is a bioactive triterpenoid saponin from Panax ginseng with diverse pharmacological properties, including anti-diabetic, sleep-promoting, and anti-tumor activities. It is a potential modulator of cellular processes and has been studied for its role in metabolic and neurological disorders. |
| Molecular Formula |
C53H90O22
|
|---|---|
| Molecular Weight |
1079.28
|
| Exact Mass |
1078.592
|
| CAS # |
11021-14-0
|
| PubChem CID |
12855889
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1128.3±65.0 °C at 760 mmHg
|
| Flash Point |
636.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
75
|
| Complexity |
1950
|
| Defined Atom Stereocenter Count |
29
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H](O8)CO)O)O)O)O)O)C
|
| InChi Key |
JDCPEKQWFDWQLI-LUQKBWBOSA-N
|
| InChi Code |
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
NSC-310104 NSC310104 NSC 310104
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~92.66 mM)
H2O : ~50 mg/mL (~46.33 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (30.88 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9265 mL | 4.6327 mL | 9.2654 mL | |
| 5 mM | 0.1853 mL | 0.9265 mL | 1.8531 mL | |
| 10 mM | 0.0927 mL | 0.4633 mL | 0.9265 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
